1y return+59.5%S&P 500 +20.9%
3y return+30.4%S&P 500 +68.5%
5y return+1.8%S&P 500 +74.5%
10y return+6.2%S&P 500 +256.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since June 30, 2016: $106 against $357 in the S&P 500.2
Birchview Capital, LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| KLACKla Corporation | $53.8M | 25.2% | +797.6% |
| BMYBristol-myers Squibb Co | $17.1M | 8.0% | −2.9% |
| LRCXLam Research Corporation | $15.2M | 7.1% | −2.8% |
| NTLAIntellia Therapeutics Inc | $6.8M | 3.2% | −13.4% |
| SLDBSolid Biosciences Inc | $6.7M | 3.1% | +6.4% |
| Biodesix IncCUSIP 09075X108 | $6.5M | 3.0% | |
| STOKStoke Therapeutics Inc | $5.8M | 2.7% | −15.2% |
| OVVOvintiv Inc | $5.7M | 2.6% | |
| NKTRNektar Therapeutics | $5.7M | 2.6% | +161.3% |
| CORTCorcept Therapeutics Inc | $5.0M | 2.3% | +21.2% |
| NBIXNeurocrine Biosciences Inc | $4.6M | 2.1% | |
| Prothena Corp PLCCUSIP G72800108 | $4.4M | 2.1% | |
| ACADAcadia Pharmaceuticals Inc | $4.3M | 2.0% | |
| PTGXProtagonist Therapeutics Inc | $4.3M | 2.0% | |
| CMPXCompass Therapeutics Inc | $3.7M | 1.7% | +14.3% |
| RLMDRelmada Therapeutics Inc | $2.8M | 1.3% | |
| Alkermes PLCCUSIP G01767105 | $2.6M | 1.2% | |
| HALOHalozyme Therapeutics Inc | $2.6M | 1.2% | +229.2% |
| CLDXCelldex Therapeutics Inc | $2.6M | 1.2% | |
| CYTKCytokinetics Inc | $2.6M | 1.2% | |
| OLMAOlema Pharmaceuticals Inc | $2.5M | 1.2% | −9.1% |
| VERAVera Therapeutics Inc | $2.5M | 1.2% | +31.3% |
| UTHRUnited Therapeutics Corp | $2.4M | 1.1% | |
| ZBIOZenas Biopharma Inc | $2.4M | 1.1% | +33.7% |
| Uniqure NvCUSIP N90064101 | $2.3M | 1.1% | −49.7% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| OVVOvintiv Inc | June 30, 2020 | +451.5% | $5.7M |
| CORTCorcept Therapeutics Inc | June 30, 2020 | +416.9% | $5.0M |
| PTGXProtagonist Therapeutics Inc | March 31, 2021 | +373.3% | $4.3M |
| UTHRUnited Therapeutics Corp | June 30, 2020 | +347.8% | $2.4M |
| CYTKCytokinetics Inc | June 30, 2021 | +330.5% | $2.6M |
| AXSMAxsome Therapeutics Inc | March 31, 2024 | +206.7% | $1.5M |
| OLMAOlema Pharmaceuticals Inc | June 30, 2025 | +193.7% | $2.5M |
| Alkermes PLCCUSIP G01767105 | March 31, 2021 | +180.5% | $2.6M |
| SLDBSolid Biosciences Inc | March 31, 2025 | +170.0% | $6.7M |
| GPCRStructure Therapeutics Inc | June 30, 2025 | +158.8% | $1.3M |
Sold off last quarter
- Novocure LtdCUSIP G6674U108 was $2.2M
- Engene Holdings IncCUSIP 29286M105 was $1.7M
- RAREUltragenyx Pharmaceutical Inc was $1.3M
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $1.1M
- VSTMVerastem Inc was $795K
- Apogee Therapeutics IncCUSIP 03770N101 was $758K
- Apellis Pharmaceuticals IncCUSIP 03753U106 was $563K
- IDYAIdeaya Biosciences Inc was $562K
- RCUSArcus Biosciences Inc was $559K
- RGNXRegenxbio Inc was $555K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +16.4% | +14.8% |
| March 31, 2026 | +3.6% | −4.6% |
| December 31, 2025 | +15.8% | +2.4% |
| September 30, 2025 | +14.2% | +7.8% |
| June 30, 2025 | −13.7% | +10.5% |
| March 31, 2025 | −5.0% | −4.6% |
| December 31, 2024 | +2.9% | +2.1% |
| September 30, 2024 | +12.0% | +5.4% |
| June 30, 2024 | −6.5% | +4.0% |
| March 31, 2024 | −0.8% | +10.0% |
| December 31, 2023 | +5.4% | +11.2% |
| September 30, 2023 | −11.4% | −3.6% |
| June 30, 2023 | −0.6% | +8.3% |
| March 31, 2023 | −6.4% | +7.0% |
| December 31, 2022 | −2.4% | +7.1% |
| September 30, 2022 | +3.3% | −5.3% |
| June 30, 2022 | −3.3% | −16.5% |
| March 31, 2022 | −1.2% | −4.9% |
| December 31, 2021 | −0.6% | +10.7% |
| September 30, 2021 | −12.4% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Birchview Capital, LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1618205&type=13F-HR&dateb=&owner=include&count=40CIK 1618205
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1618205/000161820526000003/Filed August 14, 2026 · accession 0001618205-26-000003